| Diana M Raub, MD | |
|
20397 Route 19 Ste 330, Cranberry Twp, PA 16066-6133 | |
| (724) 772-3300 | |
| (724) 772-3360 |
| Full Name | Diana M Raub |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 20397 Route 19 Ste 330, Cranberry Twp, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083935282 | NPI | - | NPPES |
| 102847441 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS016674 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Allegheny General Hospital | Pittsburgh, PA | Hospital |
| Magee Womens Hospital Of Upmc Health System | Pittsburgh, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allegheny Clinic | 5395649586 | 1941 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A new study suggests that the test used in the Italian national bowel cancer screening programme may be less likely to spot cancerous changes in summer than it is in winter.
Each year millions of people worldwide suffer from stroke, which can occur to anyone at any time. While some may recover completely, the majority of survivors will experience some form of impairment that requires a lengthy process toward partial or full recovery of functioning. Therefore, continuous improvement of rehabilitation methods is needed to ensure more positive long-term outcomes among survivors.
Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.
Bioness Inc., today announced the commercial release of its NESS L300 Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300 Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.
› Verified 3 days ago
| Entity Name | Allegheny Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073081493 PECOS PAC ID: 5395649586 Enrollment ID: O20040310000602 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A new study suggests that the test used in the Italian national bowel cancer screening programme may be less likely to spot cancerous changes in summer than it is in winter.
Each year millions of people worldwide suffer from stroke, which can occur to anyone at any time. While some may recover completely, the majority of survivors will experience some form of impairment that requires a lengthy process toward partial or full recovery of functioning. Therefore, continuous improvement of rehabilitation methods is needed to ensure more positive long-term outcomes among survivors.
Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.
Bioness Inc., today announced the commercial release of its NESS L300 Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300 Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Diana M Raub, MD 20397 Route 19 Ste 330, Cranberry Twp, PA 16066-6133 Ph: (724) 772-3300 | Diana M Raub, MD 20397 Route 19 Ste 330, Cranberry Twp, PA 16066-6133 Ph: (724) 772-3300 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
A new study suggests that the test used in the Italian national bowel cancer screening programme may be less likely to spot cancerous changes in summer than it is in winter.
Each year millions of people worldwide suffer from stroke, which can occur to anyone at any time. While some may recover completely, the majority of survivors will experience some form of impairment that requires a lengthy process toward partial or full recovery of functioning. Therefore, continuous improvement of rehabilitation methods is needed to ensure more positive long-term outcomes among survivors.
Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.
Bioness Inc., today announced the commercial release of its NESS L300 Plus System. Cleared by the U.S. Food and Drug Administration (FDA) earlier this year, the L300 Plus combines the award winning NESS L300 Foot Drop System with a thigh cuff to activate even more of the nerves and muscles in the leg for greater control while walking.
› Verified 3 days ago
Philip Iozzi, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 20630 Route 19, Suite 101, Cranberry Twp, PA 16066 Phone: 724-779-2273 | |
Sathiavathi S. Natarajan, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 20397 Route 19, 2 Landmark North, Suite 330, Cranberry Twp, PA 16066 Phone: 724-772-3300 Fax: 724-772-3360 | |
Ms. Lynne Rochelle Hricik, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 213 Executive Dr Ste 240, Cranberry Twp, PA 16066 Phone: 724-772-9797 Fax: 724-772-3309 | |
Dr. Barbara Ellen Fardo, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 213 Executive Dr, Suite 200, Cranberry Twp, PA 16066 Phone: 724-741-0044 Fax: 724-741-0040 |